Company history

2016:
Two strong clinical studies presented at the AUA
1) Prostate Cancer patient will increase quality of life by having the Memokath Ureter solution instead of e.g. JJ (Prof. Osther among others)

From the AUA 2016
Abstract: PD19-08
Introduction and Objectives
Traditional treatment options for management of malignant ureteral obstruction in prostate cancer include percutaneous nephrostomy and JJ-stenting with known morbidities and the need for frequent replacements. The objective of this study was to prospectively evaluate a new dual thermo-expandable nickel-titanium alloy metal stent (Memokath® Double Cone) for long-term treatment of distal ureteral obstruction due to prostate cancer
Conclusions
Malignant ureteral obstruction due to prostate cancer remains a complex clinical challenge. JJ-stenting and nephrostomies have significant quality of life aspects, and JJ stents often do not drain sufficiently. In this prospective series including renographic evaluation of renal split function and drainage before and after insertion, the new Memokath® Double Cone has shown a unique potential for long-term management of malignant ureteral obstruction due to prostate cancer.         

2) Showing that Memokath Ureter solution should be the preferred solution when changing the JJ stent (Prof. Stenzl beside among others)

From the AUA 2016:
Abstract: MP34-09 Introduction and Objectives Several benigne and maligne conditions can cause an upper urinary tract obstruction. Normally it is treated by inseration of a nephrostomy or pigtail catheter as well as surgical correction, which can involve several complications. The Memokath 051 is a thermo-expandable titanium-nickel spiral which can be used for treatment of long-term ureteric strictures. 
Conclusions The mentioned thermos-expandable spiral system Memokath 051 is a save and easily applicable tool for treatment of long-term ureteric strictures in patients without the possibility for surgical correction due to severe comorbidities. In contrast to the treatment with nephrostomy or pigtail catheter, which have to be changed regulary, patients with the Memokath system benefit from the extended duration of implantation.

2016:
Received the unique DRG in Denmark
DRG Codes received specially for the Memokath Ureter solution in Denmark - Unique code obtained starting from January 2017.

2015:
Registration in China
Registration approved by the CFDA for the full range of Memokath.

2014:
Karl Storz Corporation in Japan
Targeting private clinics without using X-ray when inserting Memokath - Pnn Medical/Kysmaq (the Memokath Partner in Japan) and Karl Storz. A strong combination by using Karl Storz's latest Portable Flexible Cystoscope to insert the Memokath.

2013:
Divestment
Sale of the female catheter Emteva to Hunter Urology.

2012:
Aquisition
100% Acquisition of the German Company SMP GmbH, in order to secure full control of the manufacture of the metal stent part of the Memokath™ product line.

2009:
New product - Memocore™ 066 stent marker
In the end of 2009 the Memocore™ 066 stent marker was CE-marked and introduced to the Danish market. The Memocore™ 066 is a stent marker used for the treatment of prostate cancer.

Demerger from Pnn Medical SA (Formerly Walsteen Medical SA)
The company demerged from the former Wallsten Medical SA. Pnn Medical A/S will focus on the development, production and sales & marketing of the Memokath™ urology stents as well as development of the Memocore™ (EBRT) stent marker. The Cavaterm™ business will be operated by the Swiss company Pnn Medial SA.

2007:
New identity
The company name is changed from Engineers & Doctors Wallsten Medical to: Pnn Medical A/S.

2005:
Merger between Engineers & Doctors A/S and Wallsten Medical SA
Having experienced heavy expansion and increased interest in the market for Minimal Invasive Treatment, Engineers & Doctors A/S decided to merge with the Swiss company, Wallsten Medical SA in May 2005.

2003
:
Launch of the female catheter, emteva™
In 2003 the world's first 100% biodegradable catheter for women, emteva™, was test-launched in Denmark.

Establishment of Engineers & Doctors, Inc.

2003 also saw the establishment of Engineers & Doctors, Inc. in Chesapeake, VA, USA. The company was formed to assist in the management of clinical trials in the USA.

1997:
Establishment of SMP GmbH

In 1997 the German company SMP GmbH was established to secure full control of the manufacture of the metal stent part of the Memokath™ product line.

1995:
Introduction of the third generation Memokath™ stent
In 1995 the third generation Memokath™ stent was marketed for the treatment of obstruction in the ureteric level.

1992:
Introduction of the second generation Memokath™
In 1992 Engineers & Doctors introduced the second generation urological stent, the Memokath™. It was the world's first Nickel-Titanium long-term yet always removable stent. Clinical tests were arranged and confirmed the benefits of the Memokath™ stent as a safe and effective treatment for prostate obstruction due to Benign Prostatic Hyperplasia (BPH). Further technical refinement of the Memokath™ stent was applied to make Memokath™ competitive with regard to clinical outcome.

1987:
Engineers & Doctors A/S was founded
Engineers & Doctors was founded in 1987 by polymer engineer Erik Othel-Jacobsen and medical doctor Henrik Harboe. The mission was to develop equipment for Minimal Invasive Treatment of medically recognised diseases focusing on implants and other mechanical devices.
In collaboration with Herlev University Hospital in Copenhagen, Engineers & Doctors developed the first generation stent, the Prostakath™.